LEADER 01438nam--2200409---450- 001 990000867800203316 005 20100722115235.0 010 $a88-348-6176-0 035 $a0086780 035 $aUSA010086780 035 $a(ALEPH)000086780USA01 035 $a0086780 100 $a20020111h----1996km-y0itay0103----ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $aEsperienza in tema di bilancio sociale$e"il modella francese"$fLuisa Pulejo 210 $aTorino$cG. Giappichelli$h1996 215 $a199 p.$c1 c. di tav. ripieg.$d24 cm 225 2 $aCollana di studi e ricerche dell'Istituto di economia aziendale dell'Università di Messina$v9 410 $12001$aCollana di studi e ricerche dell'Istituto di economia aziendale dell'Università di Messina$v9 461 1$1001-------$12001 606 0 $aImprese$xGestione$yFrancia$xAspetti sociali 606 0 $aBilancio$yFrancia 676 $a658.408 700 1$aPULEJO,$bLuisa$0382200 801 0$aIT$bsalbc$gISBD 912 $a990000867800203316 951 $aXXX.B. Coll. 149/ 1 (X 10 XIX 9)$b5421 EC$cXXX.B. Coll. 149/ 1 (X 10 XIX)$d00173808 959 $aBK 969 $aECO 979 $aPATTY$b90$c20020111$lUSA01$h1219 979 $c20020403$lUSA01$h1731 979 $aPATRY$b90$c20040406$lUSA01$h1700 979 $aRSIAV4$b90$c20100722$lUSA01$h1152 996 $aEsperienza in tema di bilancio sociale$9969358 997 $aUNISA LEADER 01197nam 2200325Ia 450 001 996395931203316 005 20200824125112.0 035 $a(CKB)4330000000324396 035 $a(EEBO)2248540357 035 $a(OCoLC)ocm12774388e 035 $a(OCoLC)12774388 035 $a(EXLCZ)994330000000324396 100 $a19851108d1695 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 10$aBatteries upon the kingdom of the devil$b[electronic resource] $eseasonable discourses upon some common, but woful, instances, wherein men gratifie the grand enemy of their salvation /$fby Mr. Cotton Mather .. 210 $aLondon $cPrinted for Nath. Hiller ...$d1695 215 $a[17], 192 p 300 $aReproduction of original in British Library. 300 $aPages 183-end of book are lacking in filmed copy. Pages 170-end of book photographed from New York Public Library copy and inserted at end. 330 $aeebo-0018 700 $aMather$b Cotton$f1663-1728.$0275561 801 0$bEAA 801 1$bEAA 801 2$bm/c 801 2$bWaOLN 906 $aBOOK 912 $a996395931203316 996 $aBatteries upon the kingdom of the devil$92313734 997 $aUNISA LEADER 03639nam 22006135 450 001 9910420948603321 005 20230412150948.0 010 $a3-030-56619-6 024 7 $a10.1007/978-3-030-56619-7 035 $a(CKB)4100000011469492 035 $a(MiAaPQ)EBC6356684 035 $a(DE-He213)978-3-030-56619-7 035 $a(PPN)269661204 035 $a(EXLCZ)994100000011469492 100 $a20200923d2020 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases$b[electronic resource] /$fedited by Christopher L. Cioffi 205 $a1st ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (IX, 272 p. 1 illus.) 225 1 $aTopics in Medicinal Chemistry,$x1862-247X ;$v35 311 $a3-030-56618-8 327 $aAn Overview of Retinal Diseases and Current Ocular Drug Discovery -- Ocular Pharmacokinetics and Drug Delivery Challenges -- Models of Pathologies Associated with Age-related Macular Degeneration and Their Utilities in Drug Discovery -- Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease -- Targets and Strategies toward the Development of Therapeutics for Diabetic Retinopathy and Diabetic Macular Edema -- Recent Developments for the Treatment of Glaucoma -- Emerging Gene Therapy Treatments for Retinal Degenerative Diseases. . 330 $aThis book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery. In this volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerging gene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy. 410 0$aTopics in Medicinal Chemistry,$x1862-247X ;$v35 606 $aMedicinal chemistry 606 $aOphthalmology 606 $aPharmaceutical chemistry 606 $aMedical genetics 606 $aMedicinal Chemistry 606 $aOphthalmology 606 $aPharmaceutics 606 $aClinical Genetics 615 0$aMedicinal chemistry. 615 0$aOphthalmology. 615 0$aPharmaceutical chemistry. 615 0$aMedical genetics. 615 14$aMedicinal Chemistry. 615 24$aOphthalmology. 615 24$aPharmaceutics. 615 24$aClinical Genetics. 676 $a615.19 702 $aCioffi$b Christopher L. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910420948603321 996 $aDrug delivery challenges and novel therapeutic approaches for retinal diseases$92520068 997 $aUNINA